# A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

> **NCT04543305** · PHASE1 · COMPLETED · sponsor: **Prelude Therapeutics** · enrollment: 16 (actual)

## Conditions studied

- Multiple Myeloma
- Acute Myeloid Leukemia
- Non Hodgkin Lymphoma
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** PRT1419

## Key facts

- **NCT ID:** NCT04543305
- **Lead sponsor:** Prelude Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-28
- **Primary completion:** 2022-03-21
- **Final completion:** 2022-03-21
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04543305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04543305, "A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04543305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*